Chip-concentrated stocks clustered in four major industries, and 43 stocks fell for more than three consecutive periods. According to the statistics of Securities Times and DataBao, as of December 12, 300 stocks disclosed the number of shareholders in the latest period, compared with the previous period (November 30), there were 162 stocks with a decrease in the number of shareholders. Specifically, the number of shareholders in 29 stocks decreased by more than 5%, and the number of shareholders in 5 stocks decreased by more than 10%, including Dongfang Huanyu, Zhongshe, Baina Qiancheng, Midland New Materials and Hengshuai. Many chip-concentrated stocks have performed well in the recent market. According to the statistics of DataBao, the average share capital of 126 chips has increased by 4.86% since last month, and the cumulative increase of 18 stocks is above 10%. The top gainers are Guoan Da, Beiwei Technology and Silk Road Vision, which have increased by 42.5%, 26.18% and 21.44% respectively. From the industry point of view, the number of chip concentrated stocks is the largest in the four major industries of mechanical equipment, power equipment, electronics, medicine and biology.Tianmao Group: The premium income of Guohua Life Insurance in 2024 was about 32.694 billion yuan. Tianmao Group announced that the accumulated original insurance premium income of Guohua Life Insurance Co., Ltd., a holding subsidiary of the company, was about 32.694 billion yuan from January 1, 2024 to November 30, 2024. The above-mentioned original insurance premium income data has not been audited.Thirteen companies disclosed the progress of repurchase, among which Green Energy Huichong and Ruike had the highest amount of laser repurchase plans. On December 13th, a total of 13 companies issued announcements on stock repurchase. Among them, two companies disclosed the stock repurchase plan for the first time, four companies disclosed the progress of the implementation of stock repurchase, and seven companies have completed the implementation of the repurchase plan. Judging from the initial disclosure of the repurchase plan, Green Energy Huichong and Ruike Laser have the highest amount of repurchase plans, with the planned repurchase not exceeding 1.115 million yuan and 487,900 yuan respectively. Judging from the implementation progress of repurchase, Yuanli Technology, Jiuli Special Materials and Jack have the highest share repurchase amounts, with 33.1077 million yuan, 30.9807 million yuan and 3.2323 million yuan respectively. Judging from the completed repurchase, a total of one company repurchased more than 10 million on that day. Aerospace Rainbow, Aerospace Rainbow and Guanshi Technology have completed the highest repurchase amount, with 33.2989 million yuan, 2.479 million yuan and 2.1642 million yuan respectively.
The Central Committee of the Communist Party of Vietnam decided to give disciplinary punishment and warning to former president Ruan Chunfu. On December 13th, local time, the Political Bureau of the Central Committee of the Communist Party of Vietnam announced the review results and disciplinary decision of former president Ruan Chunfu and former permanent secretary of the Central Secretariat and director of the Central Organization Department Zhang Shimei. After reviewing the recommendations of the Central Inspection Commission, the Political Bureau of the Central Committee of the Communist Party of Vietnam decided to give disciplinary action and warning to Ruan Chunfu and criticize Zhang Shimei. (CCTV News)Haitong Securities: The moderate price reduction of traditional Chinese medicine varieties continues. The domestic pharmaceutical industry is expected to set off a wave of mergers and acquisitions. Haitong Securities released a research report saying that the moderate price reduction of traditional Chinese medicine varieties continues. In 2024, the traditional Chinese medicine industry was under pressure due to the pressure of pharmacy terminal sales and inventory pressure, and it is expected to return to a good situation in the next 25 years. In addition, the continuous technological changes in the pharmaceutical industry, the development of IPO to mergers and acquisitions and the promotion of corporate governance optimization at the shareholder level are the main reasons for promoting mergers and acquisitions in the industry. In terms of fields, mergers and acquisitions are expected to occur intensively in sub-sectors such as medical devices, Chinese medicine, medical services, blood products and scientific research services.Broadcom's share price rose more than 10% after the US market closed.
Broadcom's share price rose to 15% in the US after hours.The US dollar index rose by 0.3%, the Japanese yen fell to 153, and the Swiss franc fell by over 0.9%. On Thursday (December 12), the ICE dollar index rose by 0.31% to 107.038 points, and the intraday trading range was 106.354-107.041 points. The whole day showed a volatile upward state, but the European Central Bank announced a rate cut, the US PPI data was released, and Beijing. The Bloomberg dollar index rose by 0.28%, reaching a daily high of 1288.41 points, and then fluctuated upward after reaching a daily low of 1281.12 points at 15:17. The dollar rose 0.14% against the yen to 152.67 yen, and the intraday trading range was 151.81-152.77 yen. The euro fell 0.27% to 1.0467, the pound fell 0.62% to 1.2673, and the dollar rose 0.93% to 0.8924 against the Swiss franc. Among the commodity currencies, the Australian dollar was roughly flat after falling back against the US dollar, while the New Zealand dollar fell by 0.29% and the US dollar rose by 0.44% against the Canadian dollar. The Swedish krona fell 0.38% against the US dollar, while the Norwegian krona fell 0.26% against the US dollar.Pfizer announced an increase in its quarterly dividend, and American pharmaceutical giant Pfizer said on Thursday that it would increase its quarterly dividend by 2.4%, from 42 cents to 43 cents per share. The new dividend is equivalent to $1.72 per year, which means that the annual yield is about 6.8%. Albert Bourla, CEO of Pfizer, said that the dividend increase highlighted the company's strong financial performance, execution and commitment to return capital to shareholders.